

Electronic Supporting Information

Synthesis, structures and cytotoxic effects *in vitro* of *cis*- and *trans*-[Pt^{IV}Cl₄(NHC)₂] complexes and their Pt^{II} precursors

Tobias Rehm,^a Matthias Rothemund,^a Thomas Dietel,^b Rhett Kempe^b and Rainer Schobert^a

^aOrganic Chemistry Laboratory, University Bayreuth, Universitaetsstrasse 30, 95440 Bayreuth, Germany. E-mail: Rainer.Schobert@uni-bayreuth.de

^bLehrstuhl fuer Anorganische Chemie II, University Bayreuth, Universitaetsstrasse 30, 95440 Bayreuth, Germany.

Table of content

Single crystal X-ray diffraction data of complexes 2c and 3 (Table S1)	S2
NMR spectra of complexes 2a-d , <i>trans</i> - 2c , 3 , 4a-d and <i>trans</i> - 4c (Fig. S1-S30)	S3–S17
Oxidation of complex 2b with NaOCl	S18–S21
Stability of complex 4b in DMSO / water	S22–S24
Confirmative MTT-assays with 2c / 2d (Table S2)	S25

Table S 1: Single crystal X-ray diffraction data of platinum carbene complexes **2c** and **3**.

Crystal data	2c	3
Chemical formula	C ₃₀ H ₄₄ Cl ₂ N ₄ Pt·CHCl ₃	C ₃₄ H ₃₂ Cl ₄ N ₄ Pt·2(CH ₂ Cl ₂)
<i>M_r</i>	846.07	983.87
Crystal system, space group	Triclinic, P	Monoclinic, C2/c
Temperature (K)	133	133
<i>a</i> , <i>b</i> , <i>c</i> (Å)	8.6162 (17), 12.200 (2), 17.892 (4)	24.684 (5), 8.277 (5), 22.505 (5)
α , β , γ (°)	104.49 (3), 95.13 (3), 104.88 (3)	121.662 (5)
<i>V</i> (Å ³)	1736.1 (7)	3914 (3)
<i>Z</i>	2	4
<i>F</i> (000)	842.5	1945
<i>D_x</i> (Mg m ⁻³)	1.618	1.670
Radiation type	Mo K α	Mo K α
No. of reflections for cell measurement	1222	8743
θ range (°) for cell measurement	5.7–25.8	1.9–28.3
μ (mm ⁻¹)	4.45	3.81
Crystal shape	Block	Block
Colour	Clear colourless	Colourless
Crystal size (mm)	0.07 × 0.01 × 0.004	0.21 × 0.12 × 0.09
Data collection		
Diffractometer	STOE-STADIVARI	STOE-STADIVARI
Scan method	ω scans	ω scan
Absorption correction	Numerical	Numerical
<i>T_{min}</i> , <i>T_{max}</i>	0.613, 0.733	0.841, 0.912
No. of measured, independent and observed [<i>I</i> > 2 σ (<i>I</i>)] reflections	20838, 8234, 7605	10695, 3414, 2307
<i>R_{int}</i>	0.015	0.077
θ values (°)	θ_{\max} = 28.5, θ_{\min} = 1.8	θ_{\max} = 25.0, θ_{\min} = 2.0
($\sin \theta/\lambda$) _{max} (Å ⁻¹)	0.671	0.595
Range of <i>h</i> , <i>k</i> , <i>l</i>	<i>h</i> = -11 → 7 <i>k</i> = -16 → 16 <i>l</i> = -23 → 22	<i>h</i> = -29 → 29 <i>k</i> = -5 → 9 <i>l</i> = -26 → 22
Refinement		
Refinement on	<i>F</i> ²	<i>F</i> ²
<i>R</i> [<i>F</i> ² > 2 σ (<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i>	0.018, 0.038, 1.04	0.055, 0.163, 0.99
No. of reflections	8234	3414
No. of parameters	374	223
No. of restraints	0	18
H-atom treatment	H-atom parameters constrained	H-atom parameters constrained
Weighting scheme	$w = 1/[\sigma^2(\text{Fo}^2) + (0.0198\text{P})^2 + 0.8853\text{P}]$ where P = (Fo ² + 2Fc ²)/3	$w = 1/[\sigma^2(\text{Fo}^2) + (0.1072\text{P})^2]$ where P = (Fo ² + 2Fc ²)/3
(Δ/σ) _{max}	< 0.001	< 0.001
$\Delta\rho_{\max}$, $\Delta\rho_{\min}$ (e Å ⁻³)	0.62, -0.54	2.14, -2.78




Fig. S 1: $^1\text{H-NMR}$ spectrum (500 MHz, $\text{DMSO-}d_6$) of complex **2a**.




Fig. S 2: $^{13}\text{C-NMR}$ spectrum (126 MHz, CDCl_3) of complex **2a**.




Fig. S 3: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **2a**.




Fig. S 4: ^1H -NMR spectrum (500 MHz, CDCl_3) of complex **2b**.




Fig. S 5: ^{13}C -NMR spectrum (126 MHz, CDCl_3) of complex **2b**.




Fig. S 6: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **2b**.




Fig. S 7: $^1\text{H-NMR}$ spectrum (500 MHz, CDCl_3) of complex **2c**.




Fig. S 8: $^{13}\text{C-NMR}$ spectrum (126 MHz, CDCl_3) of complex **2c**.




Fig. S 9: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **2c**.




Fig. S 10: ^1H -NMR spectrum (500 MHz, CDCl_3) of complex **2d**.




Fig. S 11: ^{13}C -NMR spectrum (126 MHz, CDCl_3) of complex **2d**.




Fig. S 12: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **2d**.




Fig. S 13: $^1\text{H-NMR}$ spectrum (500 MHz, $\text{DMSO-}d_6$) of complex 3.




Fig. S 14: $^{13}\text{C-NMR}$ spectrum (126 MHz, $\text{DMSO-}d_6$) of complex 3.




Fig. S 15: ^{195}Pt -NMR spectrum (108 MHz, $\text{DMSO-}d_6$) of complex **3**.




Fig. S 16: ^1H -NMR spectrum (500 MHz, CDCl_3) of complex **4b**.




Fig. S 17: ^{13}C -NMR spectrum (126 MHz, CDCl_3) of complex **4b**.




Fig. S 18: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **4b**.




Fig. S 19: $^1\text{H-NMR}$ spectrum (500 MHz, CDCl_3) of complex **4c**.




Fig. S 20: $^{13}\text{C-NMR}$ spectrum (126 MHz, CDCl_3) of complex **4c**.




Fig. S 21: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **4c**.




Fig. S 22: ^1H -NMR spectrum (500 MHz, CDCl_3) of complex **4d**.




Fig. S 23: ^{13}C -NMR spectrum (126 MHz, CDCl_3) of complex **4d**.




Fig. S 24: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex **4d**.




Fig. S 25: $^1\text{H-NMR}$ spectrum (500 MHz, CDCl_3) of complex *trans-2c*.




Fig. S 26: $^{13}\text{C-NMR}$ spectrum (126 MHz, CDCl_3) of complex *trans-2c*.




Fig. S 27: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex *trans*-2c.




Fig. S 28: ^1H -NMR spectrum (500 MHz, CDCl_3) of complex *trans*-4c.




Fig. S 29: ^{13}C -NMR spectrum (126 MHz, CDCl_3) of complex *trans*-4c.




Fig. S 30: ^{195}Pt -NMR spectrum (108 MHz, CDCl_3) of complex *trans*-4c.

Oxidation of complex **2b** with NaOCl

Pt^{IV} hydroxo complexes with NHC ligands have not been published yet.

Upon treating benzylated complex **1** with H₂O₂, a new ¹⁹⁵Pt NMR signal around -855 ppm (CDCl₃) arose but the reaction was never completed and at the same time accompanied by decomposition due to cleavage of the benzyl group forming benzoic acid.

H₂O₂ oxidation of the *N*-alkylated benzimidazole-2-ylidene complexes **2** afforded only starting material even with a vast excess of peroxide (H₂O₂ or ^tBuOOH) at elevated temperatures.

By treating **2b** with NaOCl in water/acetonitrile a new compound with a ¹⁹⁵Pt NMR signal at about -905 ppm (CDCl₃) appeared, but like before, neither did the reaction go to completion nor was it possible to separate any products from residual starting materials.

In one such run, crystals of a reaction product precipitated from CDCl₃ in the NMR tube. NMR spectra of freshly prepared solutions of these crystals in DMSO-*d*₆ were in agreement with the tentative structure **8** although alternative structures cannot be excluded with certainty. The same sample five days later showed only signals of pure starting Pt^{II} complex **2b**.




Fig. S 31 red: ¹H NMR (DMSO-*d*₆) of purported Pt^{IV} hydroxo complex **8** with characteristic signals of individual N-CH₂ protons between 3.5 and 6.0 ppm caused by inequivalent axial ligands;
green: same sample five days later shows spectrum of starting Pt^{II} complex **2b**.




Fig. S 32 COSY-Spectrum of compound **8** in DMSO- d_6




Fig. S 33 HMBC-Spectrum of compound **8** in DMSO- d_6




Fig. S 34 HSQC-Spectrum of compound **8** in DMSO- d_6




Fig. S 35 JMOL-Spectrum of compound **8** in DMSO- d_6





Fig. S 36 ^{195}Pt -Spectrum of compound **8** in $\text{DMSO-}d_6$

Stability of complex 4b in DMSO / water

UV/vis spectra (Fig. S 37): were recorded of 2 mL of a 25 μ M solution of complex **4b** (from a 5 mM stock solution in DMSO) in water/DMSO (4:1) over a period of 24 h (every 5 min for the first 3 h) by means of a Cary 60 UV-Vis Spectrometer (Agilent Technologies). Absorptions are relative to a baseline set to 0 at 400 nm.



HPLC–ESI mass spectra: were recorded on a Varian 1200 Quadrupole MS/MS spectrometer of diluted NMR solutions of complex **4b** in water / DMSO- d_6 (30:70) after 0 min, 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, and 16 h. The area of the total ion current (TIC) filtered for the main decomposition species with $m/z = 579$ was calculated for each of these points in time.

Exemplary MS after 10 min:





Fig. S 38: 1. Top in red: TIC = Total Ion Current from 0-3.2 min;
2. Middle in green: peak $m/z = 579$ integrated from 0-3.2 min to give an area of 9.641×10^9
3. Bottom: spectrum 1A, pertinent to TIC from 0-3.2 min.

Exemplary MS after 16 h:





Fig. S 39: 1. Top in red: TIC = Total Ion Current from 0-3.2 min;
 2. Middle in green: peak $m/z = 579$ integrated from 0-3.2 min to give an area of 2.533×10^{10}
 3. Bottom: spectrum 1A, pertinent to TIC from 0-3.2 min.

Integration of peak $m/z = 579$ in spectra from 0-3.2 min recorded over time:

Time	Area
0 min	5.35×10^9
5 min	8.6×10^9
10 min	9.64×10^9
15 min	1.08×10^{10}
30 min	1.26×10^{10}
1 h	1.42×10^{10}
2 h	1.8×10^{10}
16 h	2.53×10^{10}

Confirmative MTT-assays with compounds 2c and 2d: were carried out with cells of the same lines yet of *distinctly different* passage numbers:

Table S 2: Means \pm SD of IC₅₀ (72 h) values [μ M] of complexes **2c** and **2d** in MTT assays against human cancer cell lines^a as calculated from four independent measurements

compounds	IC ₅₀ (72h) [μ M]	
	2c ^{10b}	2d
^a 518A2	2.1 \pm 0.3	> 50
^a HT29	10.8 \pm 1.0	> 50
^a DLD-1	17.4 \pm 1.0	> 50
^a HCT116 ^{wt}	7.0 \pm 0.8	> 50
^a HCT116 ^{-/-}	5.3 \pm 0.2	> 50

^a518A2 – melanoma, HT-29 – colon adenocarcinoma, DLD-1 – Dukes type C colorectal adenocarcinoma, HCT116^{wt} – colon carcinoma (wildtype); HCT116^{-/-} – colon carcinoma (p53 knock-out mutant).